PipelinePharma Logo

iodixanol Injection 270 mg/ml, 320 mg/ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #36649

Established in 2013, this manufacturer operates a WHO-GMP certified facility in Wardha, India. As a CTD dossier owner and manufacturer, it specializes in life-saving parenteral products, including critical care injections and contrast media for imaging procedures like angiography, CT scans, and MRIs. The GMP manufacturer emphasizes research and development, producing high-quality medicines at affordable prices. With large production capacities for ampoules, vials, and bottles, it ensures adequate supply to both domestic and international markets. As a CTD dossier owner and manufacturer, it upholds stringent quality standards and regulatory compliance.

IODIXANOL Manufacturers

Markets of interest

IODIXANOL is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. The substance is available for sale in the form of a solution for injection, from manufacturers in various countries including Y. The drug is provided by a wide range of IODIXANOL suppliers from various countries including the Y, Y, and Y. Mostly due to the availability of raw materials for the manufacturing process and low labor costs, the leading IODIXANOL manufacturers and distributors are based in China.

Licensing and brand names

Under the trade name Visipaque IODIXANOL was first approved for use in both intra-arterial and intravenous radiologic procedures on March 22, 1996. The medication is presently approved in many countries and is available in both generic and trade name versions. One of the most popular branded versions of IODIXANOL is manufactured and supplied by the Chinese pharmaceutical company JINLAN Pharm-Drugs Technology Co., Ltd. Other manufacturing companies and distributors from Argentina, Turkey have also successfully adapted to the demands of the global marketplace and produce a variant of the drug with IODIXANOL as an active ingredient.

Target supply price

The wholesale acquisition cost of Gadavist intravenous solution (604.72 mg/mL) is around $80 for a supply of 7.5 milliliters. The retail price of 550mg / ml solution for injection of 100ml N10 container in Europe reaches 663.45 EUR. The medication wholesale prices and commercial terms can vary depending on the supplier. The medication wholesale prices and commercial terms can vary depending on the supplier.

Information from manufacturers

We provide a detailed list of the IODIXANOL manufacturers and suppliers that you are looking for. You can also find the dossier status of IODIXANOL and the GMP approvals of the different variants of the medication. The product description of all IODIXANOL suppliers contains essential information about the medication you order including clinical data, stability zones, and a list of countries where IODIXANOL is already registered in. Manufacturers also specify the commercial terms of their offers, such as the market for which the offer is intended, deal type, dossier licensing fee, supply price, payment terms as well as delivery terms. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified Follicle-stimulating hormone suppliers and distributors enter our online marketplace, offering you a risk-free global B2B pharmaceutical sales platform.